BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis

BACKGROUND: Anti-EGFR antibody–based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations—including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification—are associated with the mechanisms underlying the development of resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Soo Kyung, Yun, Sumi, Koh, Jiwon, Kwak, Yoonjin, Seo, An Na, Park, Kyoung Un, Kim, Duck-Woo, Kang, Sung-Bum, Kim, Woo Ho, Lee, Hye Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798471/
https://www.ncbi.nlm.nih.gov/pubmed/26991109
http://dx.doi.org/10.1371/journal.pone.0151865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798471/
https://www.ncbi.nlm.nih.gov/pubmed/26991109
http://dx.doi.org/10.1371/journal.pone.0151865

Ejemplares similares